<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742144</url>
  </required_header>
  <id_info>
    <org_study_id>OMB111148</org_study_id>
    <nct_id>NCT00742144</nct_id>
  </id_info>
  <brief_title>Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia</brief_title>
  <official_title>An Open-label Phase I Study of Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This is an open-label study to evaluate safety, tolerability, efficacy and PK profile of
      ofatumumab monotherapy in Japanese follicular lymphoma (FL) or chronic lymphocytic leukemia
      (CLL) patients. subject will receive ofatumumab 8 weekly infusions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2008</start_date>
  <completion_date type="Actual">November 18, 2009</completion_date>
  <primary_completion_date type="Actual">November 18, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tolerability</measure>
    <time_frame>eight weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event,Clinical laboratory tests,Immunoglobulin,HAHA,Objective response rate,Duration of response,Progression free survival,CD5,19,20,CD23 positive cells,Complement (CH50),PK parameters,</measure>
    <time_frame>nine months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular</condition>
  <arm_group>
    <arm_group_label>ofatumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Japanese patients with CD20 positive follicular lymphoma or chronic lymphocytic leukemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ofatumumab</intervention_name>
    <description>Ofatumumab (GSK1841157), a clear colorless liquid, is supplied in a glass vial. Each vial contains 100mg of ofatumumab in 5mL.</description>
    <arm_group_label>ofatumumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Signed Informed Consent.

          -  Histologically confirmed relapsed or refractory CD20 positive FL grade 1-3a and 1 or
             more clearly demarcated lesions with a largest diameter = 1.5 cm, or CD5, CD19, CD20
             and CD23 positive relapse or refractory CLL.

          -  Subjects must have adequate blood, liver, and kidney function.

          -  Subjects who passed the provided periods from the last anti-cancer treatments at
             screening

          -  ECOG Performance Status of 0-2

          -  Life expectancy more than 24 weeks at screening

        EXCLUSION CRITERIA:

          -  Current and past malignancy other than FL and CLL within 5 years prior to screening.

          -  Known Richter's transformation

          -  Previous autologous stem cell transplantation within 24 weeks prior to screening

          -  Previous allogeneic stem cell transplantation

          -  Known CNS involvement

          -  History of significant cerebrovascular disease

          -  Current cardiac disease requiring medical treatment

          -  Chronic or ongoing active infectious disease requiring systemic treatment

          -  Patients with pleural effusion or ascites detectable by physical examination

          -  Positive serology test for any of HBsAg, anti-HBc or anti-HCV

          -  Known HIV positive

          -  Pregnant or lactating women

          -  Women of childbearing potential and male patients not willing to use adequate
             contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aichi</city>
        <zip>466-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/OMB111148?search=study&amp;study_ids=OMB111148#rs</url>
    <description>Results for study OMB111148 can be found on the GSK Clinical Study Register.</description>
  </link>
  <reference>
    <citation>Ogura M, Hatake K, Tobinai K, Uchida T, Suzuki T, Terui Y, Yokoyama M, Maruyama D, Mori M, Jewell RC, Katsura K, Hotta T. Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Jpn J Clin Oncol. 2013 May;43(5):466-75. doi: 10.1093/jjco/hyt022. Epub 2013 Feb 28.</citation>
    <PMID>23456745</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2008</study_first_submitted>
  <study_first_submitted_qc>August 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2008</study_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD20 positive</keyword>
  <keyword>Chronic lymphocytic leukemia</keyword>
  <keyword>Follicular lymphoma</keyword>
  <keyword>GSK1841157</keyword>
  <keyword>Japanese patient</keyword>
  <keyword>Ofatumumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ofatumumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

